The decrease of the “M2” markers CD163 and CD16 induced by NS1 treatment was also seen in CSF1-treated monocytes of patients with a defective NOX2 (chronic granulomatous disease CGD patients) as shown by Solier et al. [25], linking these effects to NOX2 inhibition by NS1. Here, CSF1 is linked to chronic granulomatous disease.